UroGen Pharma (NASDAQ:URGN) Price Target Cut to $55.00 by Analysts at HC Wainwright

UroGen Pharma (NASDAQ:URGN) had its price objective decreased by HC Wainwright from $64.00 to $55.00 in a report released on Tuesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other equities research analysts have also commented on the stock. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price objective on shares of UroGen Pharma in a research note on Monday. LADENBURG THALM/SH SH initiated coverage on UroGen Pharma in a research note on Wednesday, February 19th. They issued a “buy” rating and a $31.00 price target on the stock. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $38.20.

UroGen Pharma Trading Up 9.1 %

Shares of URGN stock opened at $10.82 on Tuesday. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The firm has a market capitalization of $253.77 million, a P/E ratio of -3.43 and a beta of 1.12. UroGen Pharma has a twelve month low of $9.03 and a twelve month high of $20.70. The stock’s fifty day simple moving average is $10.45 and its 200 day simple moving average is $11.70.

UroGen Pharma (NASDAQ:URGN) last posted its earnings results on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). The business had revenue of $24.57 million for the quarter, compared to analysts’ expectations of $25.25 million. As a group, sell-side analysts predict that UroGen Pharma will post -3.12 EPS for the current fiscal year.

Insider Activity

In other news, insider Mark Schoenberg sold 4,551 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the sale, the insider now directly owns 145,666 shares of the company’s stock, valued at approximately $1,622,719.24. This trade represents a 3.03 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, General Counsel Jason Drew Smith sold 7,379 shares of UroGen Pharma stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $82,202.06. Following the sale, the general counsel now owns 26,468 shares in the company, valued at $294,853.52. This represents a 21.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On UroGen Pharma

A number of hedge funds have recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS bought a new stake in UroGen Pharma in the 4th quarter worth about $59,000. Lazard Asset Management LLC purchased a new stake in shares of UroGen Pharma during the 4th quarter valued at about $67,000. BNP Paribas Financial Markets grew its stake in shares of UroGen Pharma by 221.8% in the third quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock worth $109,000 after acquiring an additional 5,890 shares during the period. Aquatic Capital Management LLC purchased a new position in shares of UroGen Pharma during the fourth quarter valued at approximately $101,000. Finally, Oppenheimer & Co. Inc. purchased a new position in shares of UroGen Pharma during the fourth quarter valued at approximately $126,000. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.